Welcome to LookChem.com Sign In|Join Free

CAS

  • or
L-3-Cyanophenylalanine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

57213-48-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 57213-48-6 Structure
  • Basic information

    1. Product Name: L-3-Cyanophenylalanine
    2. Synonyms: 3-CYANO-L-PHENYLALANINE;(M-CN)PHE-OH;M-CYANO-L-PHENYLALANINE;L-3-CYANOPHENYLALANINE;L-3-CYANOPHE;H-M-CYANO-L-PHE-OH;H-PHE(3-CN)-OH;H-PHE(M-CN)-OH
    3. CAS NO:57213-48-6
    4. Molecular Formula: C10H10N2O2
    5. Molecular Weight: 190.2
    6. EINECS: N/A
    7. Product Categories: Amino Acids;Phenylalanine analogs and other aromatic alpha amino acids;a-amino
    8. Mol File: 57213-48-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 325.7°C (rough estimate)
    3. Flash Point: 185.127 °C
    4. Appearance: White to slightly yellow/Powder
    5. Density: 1.2167 (rough estimate)
    6. Refractive Index: 1.6300 (estimate)
    7. Storage Temp.: Store at 0°C
    8. Solubility: N/A
    9. PKA: 2.14±0.10(Predicted)
    10. CAS DataBase Reference: L-3-Cyanophenylalanine(CAS DataBase Reference)
    11. NIST Chemistry Reference: L-3-Cyanophenylalanine(57213-48-6)
    12. EPA Substance Registry System: L-3-Cyanophenylalanine(57213-48-6)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 20/21/22
    3. Safety Statements: 26-37/39-37/38
    4. RIDADR: UN3439
    5. WGK Germany:
    6. RTECS:
    7. HazardClass: 6.1
    8. PackingGroup: III
    9. Hazardous Substances Data: 57213-48-6(Hazardous Substances Data)

57213-48-6 Usage

Chemical Properties

white to slightly yellow powder

Check Digit Verification of cas no

The CAS Registry Mumber 57213-48-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,2,1 and 3 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 57213-48:
(7*5)+(6*7)+(5*2)+(4*1)+(3*3)+(2*4)+(1*8)=116
116 % 10 = 6
So 57213-48-6 is a valid CAS Registry Number.

57213-48-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H27474)  3-Cyano-L-phenylalanine, 98%   

  • 57213-48-6

  • 250mg

  • 766.0CNY

  • Detail
  • Alfa Aesar

  • (H27474)  3-Cyano-L-phenylalanine, 98%   

  • 57213-48-6

  • 1g

  • 1961.0CNY

  • Detail

57213-48-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-2-Amino-3-(3-cyanophenyl)propanoic acid

1.2 Other means of identification

Product number -
Other names L-3-Cyanophenylalanine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:57213-48-6 SDS

57213-48-6Relevant articles and documents

Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1)

Chien, Huan-Chieh,Colas, Claire,Finke, Karissa,Springer, Seth,Stoner, Laura,Zur, Arik A.,Venteicher, Brooklynn,Campbell, Jerome,Hall, Colton,Flint, Andrew,Augustyn, Evan,Hernandez, Christopher,Heeren, Nathan,Hansen, Logan,Anthony, Abby,Bauer, Justine,Fotiadis, Dimitrios,Schlessinger, Avner,Giacomini, Kathleen M.,Thomas, Allen A.

supporting information, p. 7358 - 7373 (2018/08/06)

The L-type amino acid transporter 1 (LAT1, SLC7A5) transports essential amino acids across the blood-brain barrier (BBB) and into cancer cells. To utilize LAT1 for drug delivery, potent amino acid promoieties are desired, as prodrugs must compete with millimolar concentrations of endogenous amino acids. To better understand ligand-transporter interactions that could improve potency, we developed structural LAT1 models to guide the design of substituted analogues of phenylalanine and histidine. Furthermore, we evaluated the structure-activity relationship (SAR) for both enantiomers of naturally occurring LAT1 substrates. Analogues were tested in cis-inhibition and trans-stimulation cell assays to determine potency and uptake rate. Surprisingly, LAT1 can transport amino acid-like substrates with wide-ranging polarities including those containing ionizable substituents. Additionally, the rate of LAT1 transport was generally nonstereoselective even though enantiomers likely exhibit different binding modes. Our findings have broad implications to the development of new treatments for brain disorders and cancer.

METHOD FOR CLEANING 3-HYDROXYAMIDINOPHENYLALANINE DERIVATIVES BY THE PRECIPITATION AND RECRYSTALLISATION OF A SALT AND AN AROMATIC SULPHONIC ACID

-

Page/Page column 11-12, (2008/06/13)

The invention relates to a method for cleaning 3-hydroxyamidinophenylalanine derivatives comprising the steps: (a) addition of an aromatic sulphonic acid to a solution of an optionally contaminated 3-hydroxyamidinophenylalanine derivative in order to form a precipitate; (b) separation of the precipitate formed in step (a); and (c) recovery of the free 3-hydroxyamidinophenylalanine derivative from the precipitate. 3-hydroxyamidinophenylalanine derivatives can e.g. be used as urokinase inhibitors. The invention also relates to the use of highly pure 3-hydroxyamidinophenylalanine derivatives for producing 3-amidinophenylalanine derivatives.

HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS

-

Page/Page column 12, (2008/06/13)

The invention relates to novel compounds for the inhibition of the urokinase plasminogen activator (uPA) with high bioavailability and which can also be administered orally, and to the use thereof as therapeutic active ingredients for the treatment of urokinase or/and urokinase receptor associated diseases, such as, for example, tumours and metastization. The invention especially relates to compounds (I) and (II) that contain hydroxyamidine or hydroxyguanidine groups, wherein E represents a group consisting of (a).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 57213-48-6